Literature DB >> 18154530

Genetic support of extended-spectrum beta-lactamases.

L Poirel1, T Naas, P Nordmann.   

Abstract

Genes encoding extended-spectrum beta-lactamases (ESBLs) have been reported in a variety of Gram-negative species, mostly in Enterobacteriaceae, Pseudomonas aeruginosa and Acinetobacter baumannii. They are mostly either TEM or SHV derivatives, CTX-M-like enzymes--now emerging worldwide--or, less frequently, VEB, GES, and PER ESBLs. The mechanisms responsible for their acquisition are very diverse, and mostly are related to insertion sequences (ISs), transposons, class 1 integrons, and also sul1-type integrons containing the ISCR1 element. This diversity of genetic vehicles at the origin of these mobilisation/acquisition processes enhances the spread of ESBLs.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18154530     DOI: 10.1111/j.1469-0691.2007.01865.x

Source DB:  PubMed          Journal:  Clin Microbiol Infect        ISSN: 1198-743X            Impact factor:   8.067


  33 in total

1.  Further identification of CTX-M-2 extended-spectrum beta-lactamase in Pseudomonas aeruginosa.

Authors:  Renata Cristina Picão; Laurent Poirel; Ana C Gales; Patrice Nordmann
Journal:  Antimicrob Agents Chemother       Date:  2009-02-17       Impact factor: 5.191

2.  GES-13, a beta-lactamase variant possessing Lys-104 and Asn-170 in Pseudomonas aeruginosa.

Authors:  S D Kotsakis; C C Papagiannitsis; E Tzelepi; N J Legakis; V Miriagou; L S Tzouvelekis
Journal:  Antimicrob Agents Chemother       Date:  2010-01-11       Impact factor: 5.191

3.  ISCR2, another vehicle for bla(VEB) gene acquisition.

Authors:  Laurent Poirel; Pauline D Mugnier; Mark A Toleman; Timothy R Walsh; Melina J Rapoport; Alejandro Petroni; Patrice Nordmann
Journal:  Antimicrob Agents Chemother       Date:  2009-08-24       Impact factor: 5.191

4.  Functional characterization of Tn4401, a Tn3-based transposon involved in blaKPC gene mobilization.

Authors:  Gaelle Cuzon; Thierry Naas; Patrice Nordmann
Journal:  Antimicrob Agents Chemother       Date:  2011-08-15       Impact factor: 5.191

5.  First virtual screening and experimental validation of inhibitors targeting GES-5 carbapenemase.

Authors:  Francesca Spyrakis; Pierangelo Bellio; Antonio Quotadamo; Pasquale Linciano; Paolo Benedetti; Giulia D'Arrigo; Massimo Baroni; Laura Cendron; Giuseppe Celenza; Donatella Tondi
Journal:  J Comput Aided Mol Des       Date:  2019-01-02       Impact factor: 3.686

6.  Spread of Plasmids Carrying Multiple GES Variants.

Authors:  Gaelle Cuzon; Pierre Bogaerts; Caroline Bauraing; Te-Din Huang; Rémy A Bonnin; Youri Glupczynski; Thierry Naas
Journal:  Antimicrob Agents Chemother       Date:  2016-07-22       Impact factor: 5.191

7.  Nosocomial dissemination of extended-spectrum β-lactamase VEB-1a-producing Providencia stuartii isolates in a Tunisian hospital.

Authors:  H Lahlaoui; L Poirel; M B Moussa; M Ferjani; B Omrane; P Nordmann
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2011-03-27       Impact factor: 3.267

8.  CTX-M-93, a CTX-M variant lacking penicillin hydrolytic activity.

Authors:  Laura Djamdjian; Thierry Naas; Didier Tandé; Gaelle Cuzon; Catherine Hanrotel-Saliou; Patrice Nordmann
Journal:  Antimicrob Agents Chemother       Date:  2011-02-22       Impact factor: 5.191

9.  blaCTX-M genes in escherichia coli strains from Croatian Hospitals are located in new (blaCTX-M-3a) and widely spread (blaCTX-M-3a and blaCTX-M-15) genetic structures.

Authors:  Elzbieta Literacka; Branka Bedenic; Anna Baraniak; Janusz Fiett; Marija Tonkic; Ines Jajic-Bencic; Marek Gniadkowski
Journal:  Antimicrob Agents Chemother       Date:  2009-02-02       Impact factor: 5.191

10.  Evolutionary trajectories of beta-lactamase CTX-M-1 cluster enzymes: predicting antibiotic resistance.

Authors:  Angela Novais; Iñaki Comas; Fernando Baquero; Rafael Cantón; Teresa M Coque; Andrés Moya; Fernando González-Candelas; Juan-Carlos Galán
Journal:  PLoS Pathog       Date:  2010-01-22       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.